PD-1/PD-L1轴与淋巴瘤  

Programmed death-1/programmed death-ligand 1 （PD-1/PD-L1） axis and lymphoma

作　　者：王先火[1] 傅凯[1] 潘嫱 任秀宝[1] 张会来[1] 

机构地区：[1]天津医科大学肿瘤医院淋巴瘤科、国家肿瘤临床医学研究中心、天津市"肿瘤防治"重点实验室、天津市肿瘤免疫与生物治疗重点实验室、中美淋巴血液肿瘤诊治中心,300060

出　　处：《中华微生物学和免疫学杂志》2017年第5期400-404,共5页Chinese Journal of Microbiology and Immunology

基　　金：国家自然科学基金（81402945）

摘　　要：免疫检查点（immune checkpoint）已成为当今肿瘤治疗最热门的领域之一,PD-1/PD-L1轴作为免疫检查点最重要代表,已有3个抑制剂成功获得美国食品药品管理局（FDA）批准,并在多项试验中展现出巨大临床运用价值.作为来源于淋巴细胞的特殊肿瘤-淋巴瘤来说,其既有实体瘤恶性增殖的共性,又部分保留淋巴细胞包括T/B细胞的特性,故PD-1/PD-L1轴在淋巴瘤中调控机制显得更加复杂,其病理组织中表达及临床运用也显得更加扑朔迷离.本文主要阐述PD-1/PD-L1轴在淋巴瘤中特殊调控机制、病理组织表达特征、临床最新治疗进展和未来挑战.Immune checkpoints have become one of the most popular areas of cancer therapy.Programmed death-1/programmed death-ligand 1 （PD-1/PD-L1） axis is the most important representative of immune checkpoints until now, and three inhibitors of PD-1/PD-L1 axis have been successfully approved by Food and Drug Administration （FDA）.Several clinical trials have confirmed the surprising effects and great clinical application values of PD-1/PD-L1 axis inhibitors.Lymphoma that originates in lymphocytes and differs from other solid tumors has its unique characteristics.It is not only characterized by malignant proliferation, which is similar to that of other solid tumors, but also has some characteristics of lymphocytes including T/B cells.Hence, the regulatory mechanism of PD-1/PD-L1 axis is more complex in lymphoma, making the expression and clinical value of PD-1/PD-L1 in lymphoma more elusive.In this review, we focus on illustrating the specific regulation mechanisms, expression features, clinical treatment and future challenges of PD-1/PD-L1 axis in lymphoma.

关 键 词：免疫检查点 PD-1/PD-L1轴 淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]